Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Cancer Discov. 2016 Nov 21;7(1):102–113. doi: 10.1158/2159-8290.CD-16-0512

Figure 2.

Figure 2

Ipatasertib shows evidence of PD inhibition of AKT signaling in patients as evaluated by the suppression of pGSK3β in PRP. The ratio of pGSK3β to total GSK3β was evaluated in PRP from patients in all the dosing cohorts (25–800 mg) on day 1 (top) and on day 15 (bottom) of cycle 1 and was graphed as a function of time (in hours) following a single dose of ipatasertib. In all patients, pGSK3β decreased in a time-and dose-dependent manner, reaching a nadir at 2 hours after dose and remaining suppressed at 24 hours after dose. Inhibition of pGSK3β was also sustained at day 15 of dosing (bottom).